CA Stock MarketDetailed Quotes
HEM Hemostemix Inc
- 0.065
- +0.005+8.33%
15min DelayMarket Closed Dec 13 16:00 ET
9.14MMarket Cap-2.10P/E (TTM)
0.065High0.065Low35.00KVolume0.065Open0.060Pre Close2.28KTurnover0.11052wk High0.03%Turnover Ratio140.64MShares0.03552wk Low-0.031EPS TTM7.52MFloat Cap25.000Historical HighLossP/E (Static)115.63MShs Float0.035Historical Low-0.03EPS LYR0.00%Amplitude--Dividend TTM-1.05P/B1Lot Size--Div YieldTTM
About Hemostemix Inc Company
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Company Profile
SymbolHEM
Company NameHemostemix Inc
Founded2014
MarketTSX
Fiscal Year Ends12-31
Address707 - 7th Avenue SouthWest Suite 1150
CityCalgary
CountryCAN
Zip CodeT2P 3H6
Phone+1 905 580-4170
Websitehttps://www.hemostemix.com
Company Executives
- Name
- Position
- Salary
- Thomas Smeenk
- Director, President and Chief Executive Officer
- --
- Christina Wu
- Interim Chief Financial Officer
- --
- Dr. Fraser C. Henderson
- Chief Medical Officer
- --
- Peter Pavlin
- Vice President of Operations
- --
- Peter Alan Lacey
- Chairman of the Board
- --
- Loran Swanberg
- Independent Director
- --
- Dr. Ronnie Hershman
- Independent Director
- --
Heat List
CA
Overall
Symbol
Price
% Chg
No Data